Autolus Therapeutics (NASDAQ:AUTL) Upgraded at Truist Financial

Truist Financial upgraded shares of Autolus Therapeutics (NASDAQ:AUTL) to a strong-buy rating in a report issued on Wednesday,Zacks.com reports.

A number of other research analysts also recently commented on AUTL. Zacks Research upgraded Autolus Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Friday, March 13th. HC Wainwright initiated coverage on Autolus Therapeutics in a report on Tuesday, February 17th. They issued a “buy” rating and a $9.00 price objective on the stock. Needham & Company LLC decreased their target price on shares of Autolus Therapeutics from $11.00 to $10.00 and set a “buy” rating for the company in a research report on Monday, January 12th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Autolus Therapeutics in a report on Wednesday, January 21st. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $8.50.

Autolus Therapeutics Stock Performance

Autolus Therapeutics stock opened at $1.21 on Wednesday. The firm has a market capitalization of $322.03 million, a price-to-earnings ratio of -1.46 and a beta of 1.95. Autolus Therapeutics has a 52 week low of $1.11 and a 52 week high of $2.70. The company has a 50 day moving average price of $1.49 and a 200 day moving average price of $1.52.

Autolus Therapeutics (NASDAQ:AUTL) last announced its quarterly earnings data on Friday, March 27th. The company reported ($0.34) EPS for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.07). The business had revenue of $24.29 million for the quarter, compared to analyst estimates of $23.92 million. Autolus Therapeutics had a negative return on equity of 63.76% and a negative net margin of 439.69%. Equities analysts forecast that Autolus Therapeutics will post -0.94 earnings per share for the current fiscal year.

Institutional Trading of Autolus Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in AUTL. Independent Advisor Alliance acquired a new position in shares of Autolus Therapeutics during the 4th quarter worth about $28,000. Marex Group plc bought a new position in Autolus Therapeutics during the second quarter worth about $28,000. SmartHarvest Portfolios LLC bought a new stake in shares of Autolus Therapeutics in the fourth quarter worth about $43,000. Caitong International Asset Management Co. Ltd acquired a new stake in shares of Autolus Therapeutics during the third quarter worth about $46,000. Finally, R Squared Ltd lifted its holdings in shares of Autolus Therapeutics by 40.1% during the 3rd quarter. R Squared Ltd now owns 30,476 shares of the company’s stock valued at $50,000 after purchasing an additional 8,730 shares in the last quarter. Institutional investors own 72.83% of the company’s stock.

Key Autolus Therapeutics News

Here are the key news stories impacting Autolus Therapeutics this week:

• Positive Sentiment: Company reiterated 2026 guidance: management expects AUCATZYL® net product revenue of $120–$135M and a shift to positive gross margin in 2026 — a clear path to improving unit economics and cash-generation visibility. Autolus Therapeutics: Q4 Earnings Highlight Importance Of Autoimmune Data Catalysts
• Positive Sentiment: Commercial traction: AUCATZYL reported ~$23.3M net product revenue in Q4 and $74.3M for FY2025; UK launch underway after positive NICE evaluation and real‑world data show favorable activity/safety — supports revenue ramp thesis. Autolus Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates
• Positive Sentiment: Analyst upgrades/price target upside: Needham reaffirmed a Buy with a $10 PT (large theoretical upside from current levels) and Truist upgraded to Strong-Buy — these notes can attract speculative buying ahead of clinical readouts. Benzinga
• Neutral Sentiment: Pipeline catalyst timeline: pivotal Phase 2 trials enrolling in lupus nephritis and pediatric ALL; initial BOBCAT Phase 1 data in progressive MS expected late 2026 — potential upside but not immediate. Press Release
• Neutral Sentiment: Company hosted an earnings call and published the transcript/slides — useful for detail on margin assumptions and cash runway into Q4 2027. Q4 2025 Earnings Call Transcript
• Negative Sentiment: Earnings miss and weak profitability metrics: Q4 EPS of ($0.34) missed consensus ($0.27); company still deeply unprofitable with a large negative net margin and negative ROE — these metrics pressure sentiment in the near term. Press Release / Slide Deck
• Negative Sentiment: Analyst caution: Some outlets (and at least one analyst note) highlight a challenging risk/reward despite strong B-ALL data, citing reliance on upcoming autoimmune and pediatric data to re‑rate the stock. Seeking Alpha Hold-perspective

About Autolus Therapeutics

Autolus Therapeutics is a clinical-stage biopharmaceutical company specializing in the development of next-generation, programmed T cell therapies for the treatment of cancer. The company leverages proprietary technologies to engineer autologous T cells that target and eradicate tumor cells, with the aim of improving safety, efficacy and durability over existing cell therapies. Its R&D platform integrates antigen receptor design, gene editing and manufacturing optimization to generate candidates tailored for specific hematologic malignancies and solid tumor indications.

The company’s leading pipeline candidates include AUTO1, an optimized CD19-targeted CAR-T therapy for relapsed or refractory acute lymphoblastic leukemia, and AUTO3, a dual-targeted CD19/22 CAR-T program in development for diffuse large B-cell lymphoma.